Translational Basic and Clinical Research Training in Rheumatology

在流变学的转化基础和临床研究培训，在其第一个周期由纽约大学领导 流变学部主任吉尔·布约恩博士将在第二个周期根据mPI安排共同指导。 除了Buyon博士在SLE和自身免疫方面的丰富翻译经验外，Jose Scher博士还提供了 在炎症性关节炎，包括银屑病和类风湿性关节炎方面的补充专业知识。我们的使命 仍然明确：通过延长的发展期支持受训人员;利用新兴的研究 有机会吸引和激发医生;并将临床背景带到博士前的板凳上。 因此，我们的计划扩展了传统的ACGME培训，并再次提出支持2年的培训， 奖学金毕业生，加上1个博士前MD/博士候选人，以建立一个早期的管道流变学。在我们 前4年：a）3名流变学毕业生完成培训（2名晋升为纽约大学教师职位， 多年赠款和出版物，以及1个根据成就在行业中发挥领导作用; B） 2名博士前MD/PhD学员成功答辩了一篇博士论文并发表了论文; c）3名研究员和1名MD/PhD 候选人（URM）继续接受培训; d）2名纽约大学初级教师晋升为初级导师，获得新的R 01奖项 e）聘请了I型干扰素专家Timothy Niewold博士; f）增加了新的NIH研究项目， 包括临床前和临床狼疮中的P50，以及SLE中的肾和皮肤转录组学作为AMP的一部分; g） 针对新冠肺炎和风湿性疾病的临床/基础研究项目在大流行期间产生 参与培训生和教师的枢纽，因为他们承担了前所未有的病人的责任。为核心 目前的建议是跨学科的培训沿着两个方法上不同的研究轨道，每个轴承 前缀“translational”-基础或临床-强调所有医疗保健研究者的共同目的。早日 科学家途径再次提供给通过我们学校的MD/PhD和研究生招聘的MD/PhD候选人 计划，包括免疫学/炎症计划和新成立的转化研究 免疫学中心（TrIC）。培训课程以反映教师专业知识的核心疾病群为基础， 国家认可的领导：1）狼疮和系统性自身免疫性疾病; 2）炎症和 自身免疫性关节炎;和3）退行性和代谢性骨疾病。每一个都包含了共同的和 定制教学法;与小学，副，和 整合科学和医学的方法论导师;为每个人精心挑选的咨询导师委员会 培训生;并计划支持后T32教师的进步。虽然评估了方案的成功， 执行委员会会议和年度展示撤退。强有力的机构承诺支持 基础设施和额外资金。两次更新的临床/转化科学研究所提供了广泛的 资源这个T32计划代表了我们的能力建设和科学奉献的持续轨迹， 确认并扩大对风湿性疾病高级培训的承诺。

The Translational Basic and Clinical Research Training in Rheumatology, led in its first cycle by NYU Rheumatology Division Director Dr. Jill Buyon, will in its second cycle be co-directed under an mPI arrangement. Adding to Dr. Buyon’s extensive translational experience in SLE and autoimmunity, Dr. Jose Scher provides complementary expertise in inflammatory arthridities, including psoriatic and rheumatoid arthritis. Our mission remains clear: to support trainees through an extended period of development; to leverage emerging research opportunities to engage and excite physicians; and to bring clinical context to the pre-doctoral bench. Accordingly, our program extends traditional ACGME training and again proposes support for 2-yr training of 3 fellowship graduates, plus 1 predoctoral MD/PhD candidate to establish an early pipeline to rheumatology. In our first 4 years: a) 3 rheumatology graduates completed training (2 advancing to NYU faculty positions with external multi-year grants and publications, and 1 garnering a leadership role in industry based on accomplishments; b) 2 pre-doctoral MD/PhD trainees successfully defended a PhD thesis with publications; c) 3 fellows and 1 MD/PhD candidate (URM) remain in training; d) 2 NYU junior faculty advanced as Primary Mentors with new R01 awards e) Dr. Timothy Niewold, expertise in type I Interferon, was recruited; f) new NIH research programs were added, including a P50 in preclinical and clinical lupus, and renal and skin transcriptomics in SLE as part of AMP; g) clinical/basic research programs addressing COVID-19 and rheumatic diseases spawned during the pandemic engaged the pivot of trainees and faculty as they assumed unprecedented patient responsibilities. At the core of the present proposal is interdisciplinary training along 2 methodologically distinct research tracks, each bearing the prefix “translational” –basic or clinical – to emphasize the common purpose of all healthcare investigators. An Early Scientist Pathway is again offered to MD/PhD candidates recruited through our school’s MD/PhD and graduate programs, including the Immunology/Inflammation program and the newly established Translational Research Immunology Center (TrIC). Training tracks are grounded in core disease clusters reflecting faculty expertise and nationally recognized leadership: 1) lupus and diseases of systemic autoimmunity; 2) inflammatory and autoimmune arthritis; and 3) degenerative and metabolic bone disease. Each incorporates common and customized didactics; individualized research training experiences with teams of Primary, Associate, and Methodological Mentors to integrate science and medicine; a hand-picked Advisory Mentoring Committee for each trainee; and planning to support post-T32 faculty advancement. Programmatic success is evaluated though Executive Committee meetings and an Annual Showcase Retreat. Strong institutional commitment supports infrastructure and additional funding. The twice-renewed Clinical/Translational Science Institute provides extensive resources. This T32 program represents the ongoing trajectory of our capacity-building and scientific dedication, affirming and expanding commitment to advanced training in the rheumatic diseases.